Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 504532, 13 pages
http://dx.doi.org/10.1155/2014/504532
Review Article

Advanced Tracers in PET Imaging of Cardiovascular Disease

1Department of Nuclear Medicine, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China
2Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China
3Department of Orthopedics, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu 610072, China
4Sichuan Key Laboratory of Medical Imaging, North Sichuan Medical College, Nanchong 637007, China

Received 21 February 2014; Revised 7 July 2014; Accepted 8 August 2014; Published 15 October 2014

Academic Editor: Ali Gholamrezanezhad

Copyright © 2014 Yesen Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Oxenham and N. Sharpe, “Cardiovascular aging and heart failure,” European Journal of Heart Failure, vol. 5, no. 4, pp. 427–434, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Gaemperli and P. A. Kaufmann, “PET and PET/CT in cardiovascular disease,” Annals of the New York Academy of Sciences, vol. 1228, no. 1, pp. 109–136, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Schwaiger, S. I. Ziegler, and S. G. Nekolla, “PET/CT challenge for the non-invasive diagnosis of coronary artery disease,” European Journal of Radiology, vol. 73, no. 3, pp. 494–503, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. T. F. Massoud and S. S. Gambhir, “Molecular imaging in living subjects: seeing fundamental biological processes in a new light,” Genes and Development, vol. 17, no. 5, pp. 545–580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. L. W. Dobrucki and A. J. Sinusas, “PET and SPECT in cardiovascular molecular imaging,” Nature Reviews Cardiology, vol. 7, no. 1, pp. 38–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Jang, S. Park, S. H. Kang et al., “Gold nanorods for target selective SPECT/CT imaging and photothermal therapy in vivo,” Quantitative Imaging in Medicine and Surgery, vol. 2, pp. 1–11, 2012. View at Google Scholar
  7. F. J. Klocke, M. G. Baird, B. H. Lorell et al., “ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging),” Journal of the American College of Cardiology, vol. 42, no. 7, pp. 1318–1333, 2003. View at Publisher · View at Google Scholar
  8. M. M. Ter Pogossian, M. E. Phelps, E. J. Hoffman, and N. A. Mullan, “A positron emission transaxial tomograph for nuclear imaging (PETT),” Radiology, vol. 114, no. 1, pp. 89–98, 1975. View at Publisher · View at Google Scholar · View at Scopus
  9. R. H. J. A. Slart, J. J. Bax, D. J. van Veldhuisen, E. E. van der Wall, R. A. J. O. Dierckx, and P. L. Jager, “Imaging techniques in nuclear cardiology for the assessment of myocardial viability,” International Journal of Cardiovascular Imaging, vol. 22, no. 1, pp. 63–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. Ametamey, M. Honer, and P. A. Schubiger, “Molecular imaging with PET,” Chemical Reviews, vol. 108, no. 5, pp. 1501–1516, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. R. Kherlopian, T. Song, Q. Duan et al., “A review of imaging techniques for systems biology,” BMC Systems Biology, vol. 2, article 74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Dorbala, M. F. Di Carli, R. S. Beanlands et al., “Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry,” Journal of the American College of Cardiology, vol. 61, no. 2, pp. 176–184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Kobylecka, J. Ma̧czewska, K. Fronczewska-Wieniawska, T. Mazurek, M. T. Płazińska, and L. Królicki, “Myocardial viability assessment in 18FDG PET/CT study (18FDG PET myocardial viability assessment),” Nuclear Medicine Review, vol. 15, no. 1, pp. 52–60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. R. Underwood, P. de Bondt, A. Flotats et al., “The current and future status of nuclear cardiology: a consensus report,” European Heart Journal Cardiovascular Imaging, 2014. View at Publisher · View at Google Scholar
  15. I. Danad, P. G. Raijmakers, and P. Knaapen, “Diagnosing coronary artery disease with hybrid PET/CT: it takes two to tango,” Journal of Nuclear Cardiology, vol. 20, no. 5, pp. 874–890, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Flotats, J. Knuuti, M. Gutberlet et al., “Hybrid cardiac imaging: SPECT/CT and PET/CT. A joint position statement by the European Association of Nuclear Medicine (EANM), the European Society of Cardiac Radiology (ESCR) and the European Council of Nuclear Cardiology (ECNC),” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 1, pp. 201–212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. O. Ratib and R. Nkoulou, “Potential applications of PET/MR imaging in cardiology,” Journal of Nuclear Medicine, vol. 55, pp. 40S–46S, 2014. View at Google Scholar
  18. O. O. Sogbein, M. Pelletier-Galarneau, T. H. Schindler, L. Wei, R. G. Wells, and T. D. Ruddy, “New SPECT and PET radiopharmaceuticals for imaging cardiovascular disease,” BioMed Research International, vol. 2014, Article ID 942960, 25 pages, 2014. View at Publisher · View at Google Scholar
  19. A. Rahmim and H. Zaidi, “PET versus SPECT: strengths, limitations and challenges,” Nuclear Medicine Communications, vol. 29, no. 3, pp. 193–207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. G. S. Thomas and J. Maddahi, “The technetium shortage,” Journal of Nuclear Cardiology, vol. 17, no. 6, pp. 993–998, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. B. J. Pichler, H. F. Wehrl, and M. S. Judenhofer, “Latest advances in molecular imaging instrumentation,” Journal of Nuclear Medicine, vol. 49, supplement 2, pp. 5S–23S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Patton, M. Sandler, D. Berman et al., “D-SPECT: a new solid state camera for high speed molecular imaging,” The Journal of Nuclear Medicine, vol. 47, supplement 1, p. 189, 2006. View at Google Scholar
  23. P. Koepfli, T. F. Hany, C. A. Wyss et al., “CT attenuation correction for myocardial perfusion quantification using a PET/CT hybrid scanner,” Journal of Nuclear Medicine, vol. 45, no. 4, pp. 537–542, 2004. View at Google Scholar · View at Scopus
  24. C. Anagnostopoulos, A. Georgakopoulos, N. Pianou, and S. G. Nekolla, “Assessment of myocardial perfusion and viability by positron emission tomography,” International Journal of Cardiology, vol. 167, no. 5, pp. 1737–1749, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. J. L. G. C. Filho, R. de Souza Leão Lima, L. de Souza MacHado Neto, L. Kayat Bittencourt, R. C. Domingues, and L. M. B. Da Fonseca, “PET/CT and vascular disease: current concepts,” European Journal of Radiology, vol. 80, no. 1, pp. 60–67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Knešaurek, J. Machac, and J. Ho Kim, “Comparison of 2D, 3D high dose and 3D low dose gated myocardial 82Rb PET imaging,” BMC Nuclear Medicine, vol. 7, article 4, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Knešaurek, J. Machac, B. R. Krynyckyi, and O. D. Almeida, “Comparison of 2-dimensional and 3-dimensional 82Rb myocardial perfusion PET imaging,” Journal of Nuclear Medicine, vol. 44, no. 8, pp. 1350–1356, 2003. View at Google Scholar · View at Scopus
  28. A. Sánchez-Crespo, P. Andreo, and S. A. Larsson, “Positron flight in human tissues and its influence on PET image spatial resolution,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 1, pp. 44–51, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. P. A. Kaufmann, T. Gnecchi-Ruscone, J. T. Yap, O. Rimoldi, and P. G. Camici, “Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET,” Journal of Nuclear Medicine, vol. 40, no. 11, pp. 1848–1856, 1999. View at Google Scholar · View at Scopus
  30. D. K. Glover and R. J. Gropler, “Journey to find the ideal PET flow tracer for clinical use: are we there yet?” Journal of Nuclear Cardiology, vol. 14, no. 6, pp. 765–768, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Iida, I. Kanno, A. Takahashi et al., “Measurement of absolute myocardial blood flow with H215O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect,” Circulation, vol. 78, no. 1, pp. 104–115, 1988. View at Publisher · View at Google Scholar · View at Scopus
  32. E. U. Nitzsche, Y. Choi, J. Czernin, C. K. Hoh, S. Huang, and H. R. Schelbert, “Noninvasive quantification of myocardial blood flow in humans: a direct comparison of the [13N]ammonia and the [15O]water techniques,” Circulation, vol. 93, no. 11, pp. 2000–2006, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Katoh, K. Morita, T. Shiga, N. Kubo, K. Nakada, and N. Tamaki, “Improvement of algorithm for quantification of regional myocardial blood flow using15O-water with PET,” Journal of Nuclear Medicine, vol. 45, no. 11, pp. 1908–1916, 2004. View at Google Scholar · View at Scopus
  34. H. J. Harms, P. Knaapen, S. De Haan, R. Halbmeijer, A. A. Lammertsma, and M. Lubberink, “Automatic generation of absolute myocardial blood flow images using [15O]H2O and a clinical PET/CT scanner,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 5, pp. 930–939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Adachi, O. Gaemperli, I. Valenta et al., “Assessment of myocardial perfusion by dynamic O-15-labeled water PET imaging: validation of a new fast factor analysis,” Journal of Nuclear Cardiology, vol. 14, no. 5, pp. 698–705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. M. F. Di Carli, S. Dorbala, J. Meserve, G. El Fakhri, A. Sitek, and S. C. Moore, “Clinical myocardial perfusion PET/CT,” Journal of Nuclear Medicine, vol. 48, no. 5, pp. 783–793, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. H. J. Harms, S. De Haan, P. Knaapen, C. P. Allaart, A. A. Lammertsma, and M. Lubberink, “Parametric images of myocardial viability using a single 15O-H2O PET/CT scan,” Journal of Nuclear Medicine, vol. 52, no. 5, pp. 745–749, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. T. M. Bateman, G. V. Heller, A. I. McGhie et al., “Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT,” Journal of Nuclear Cardiology, vol. 13, no. 1, pp. 24–33, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. R. T. Go, T. H. Marwick, W. J. MacIntyre et al., “A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease,” Journal of Nuclear Medicine, vol. 31, no. 12, pp. 1899–1905, 1990. View at Google Scholar · View at Scopus
  40. J. Kim, P. E. Bravo, A. Gholamrezanezhad et al., “Coronary artery and thoracic aorta calcification is inversely related to coronary flow reserve as measured by 82Rb PET/CT in intermediate risk patients,” Journal of Nuclear Cardiology, vol. 20, no. 3, pp. 375–384, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. G. V. Heller, D. Calnon, and S. Dorbala, “Recent advances in cardiac PET and PET/CT myocardial perfusion imaging,” Journal of Nuclear Cardiology, vol. 16, no. 6, pp. 962–969, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Senthamizhchelvan, P. E. Bravo, C. Esaias et al., “Human biodistribution and radiation dosimetry of82Rb,” Journal of Nuclear Medicine, vol. 51, no. 10, pp. 1592–1599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Arumugam, D. Tout, and C. Tonge, “Myocardial perfusion scintigraphy using rubidium-82 positron emission tomography,” British Medical Bulletin, vol. 107, pp. 87–100, 2013. View at Publisher · View at Google Scholar
  44. R. Lautamäki, R. T. George, K. Kitagawa et al., “Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 4, pp. 576–586, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. R. A. Goldstein, N. A. Mullani, S. K. Marani, D. J. Fisher, K. L. Gould, and H. A. O'Brien Jr., “Myocardial perfusion with rubidium-82. II. Effects of metabolic and pharmacologic interventions,” Journal of Nuclear Medicine, vol. 24, no. 10, pp. 907–915, 1983. View at Google Scholar · View at Scopus
  46. J. Krivokapich, S. C. Huang, M. E. Phelps, N. S. MacDonald, and K. I. Shine, “Dependence of 13NH3 myocardial extraction and clearance on flow and metabolism,” The American Journal of Physiology, vol. 242, no. 4, pp. H536–H542, 1982. View at Google Scholar · View at Scopus
  47. H. R. Schelbert, M. E. Phelps, S. C. Huang et al., “N-13 ammonia as an indicator of myocardial blood flow,” Circulation, vol. 63, no. 6, pp. 1259–1272, 1981. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Choi, S. C. Huang, R. A. Hawkins et al., “Quantification of myocardial blood flow using 13N-ammonia and PET: comparison of tracer models,” Journal of Nuclear Medicine, vol. 40, no. 6, pp. 1045–1055, 1999. View at Google Scholar · View at Scopus
  49. B. A. Herzog, L. Husmann, I. Valenta et al., “Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve,” Journal of the American College of Cardiology, vol. 54, no. 2, pp. 150–156, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Fiechter, C. Gebhard, J. R. Ghadri et al., “Myocardial perfusion imaging with 13N-Ammonia PET is a strong predictor for outcome,” International Journal of Cardiology, vol. 167, no. 3, pp. 1023–1026, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Alexánderson, R. Jácome, M. Jiménez-Santos et al., “Evaluation of the endothelial function in hypertensive patients with 13N-ammonia PET,” Journal of Nuclear Cardiology, vol. 19, no. 5, pp. 979–986, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Fiechter, J. R. Ghadri, C. Gebhard et al., “Diagnostic value of13N-ammonia myocardial perfusion PET: added value of myocardial flow reserve,” Journal of Nuclear Medicine, vol. 53, no. 8, pp. 1230–1234, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Rauch, F. Helus, and M. Grunze, “Kinetics of 13N-ammonia uptake in myocardial single cells indicating potential limitations in its applicability as a marker of myocardial blood flow,” Circulation, vol. 71, no. 2, pp. 387–393, 1985. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Yalamanchili, E. Wexler, M. Hayes et al., “Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent,” Journal of Nuclear Cardiology, vol. 14, no. 6, pp. 782–788, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Schuler and J. E. Casida, “The insecticide target in the PSST subunit of complex I,” Pest Management Science, vol. 57, no. 10, pp. 932–940, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. M. C. Huisman, T. Higuchi, S. Reder et al., “Initial characterization of an 18F-labeled myocardial perfusion tracer,” Journal of Nuclear Medicine, vol. 49, no. 4, pp. 630–636, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Maddahi, “Properties of an ideal PET perfusion tracer: new PET tracer cases and data,” Journal of Nuclear Cardiology, vol. 19, supplement 1, pp. S30–S37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Higuchi, S. G. Nekolla, M. M. Huisman et al., “A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats,” Journal of Nuclear Medicine, vol. 49, no. 10, pp. 1715–1722, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Maddahi, J. Czernin, J. Lazewatsky et al., “Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest,” Journal of Nuclear Medicine, vol. 52, no. 9, pp. 1490–1498, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. D. S. Berman, J. Maddahi, B. K. Tamarappoo et al., “Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography,” Journal of the American College of Cardiology, vol. 61, no. 4, pp. 469–477, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Yu, M. Guaraldi, M. Kagan et al., “Assessment of 18F-labeled mitochondrial complex I inhibitors as PET myocardial perfusion imaging agents in rats, rabbits, and primates,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 1, pp. 63–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. T. Mou, H. Jing, W. Yang et al., “Preparation and biodistribution of [18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography,” Bioorganic and Medicinal Chemistry, vol. 18, no. 3, pp. 1312–1320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Madar, H. T. Ravert, Y. Du et al., “Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium,” Journal of Nuclear Medicine, vol. 47, no. 8, pp. 1359–1366, 2006. View at Google Scholar · View at Scopus
  64. T. M. Shoup, D. R. Elmaleh, A. Brownell, A. Zhu, J. L. Guerrero, and A. J. Fischman, “Evaluation of (4-[18F]Fluorophenyl)triphenylphosphonium ion. A potential myocardial blood flow agent for PET,” Molecular Imaging and Biology, vol. 13, no. 3, pp. 511–517, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. E. Tadamura, N. Tamaki, H. Okazawa et al., “Generator-produced copper-62-PTSM as a myocardial PET perfusion tracer compared with nitrogen-13-ammonia,” Journal of Nuclear Medicine, vol. 37, no. 5, pp. 729–735, 1996. View at Google Scholar · View at Scopus
  66. A. F. L. Schinkel, R. Valkema, M. L. Geleijnse, E. J. Sijbrands, and D. Poldermans, “Single-photon emission computed tomography for assessment of myocardial viability,” EuroIntervention, vol. 6, supplement G, pp. G115–G122, 2010. View at Google Scholar · View at Scopus
  67. A. Shabana and A. El-Menyar, “Myocardial viability: what we knew and what is new,” Cardiology Research and Practice, vol. 1, no. 1, Article ID 607486, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Iida, C. G. Rhodes, L. I. Araujo et al., “Noninvasive quantification of regional myocardial metabolic rate for oxygen by use of 15O2 inhalation and positron emission tomography: theory, error analysis, and application in humans,” Circulation, vol. 94, no. 4, pp. 792–807, 1996. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Yamamoto, R. de Silva, C. G. Rhodes et al., “Noninvasive quantification of regional myocardial metabolic rate of oxygen by 15O2 inhalation and positron emission tomography: experimental validation,” Circulation, vol. 94, no. 4, pp. 808–816, 1996. View at Publisher · View at Google Scholar · View at Scopus
  70. I. Grassi, C. Nanni, V. Allegri et al., “The clinical use of PET with (11)C-acetate,” American Journal of Nuclear Medicine and Molecular Imaging, vol. 2, pp. 33–47, 2012. View at Google Scholar
  71. M. Brown, D. R. Marshall, B. E. Sobel, and S. R. Bergmann, “Delineation of myocardial oxygen utilization with carbon-11-labeled acetate,” Circulation, vol. 76, no. 3, pp. 687–696, 1987. View at Publisher · View at Google Scholar · View at Scopus
  72. M. A. Brown, D. W. Myears, and S. R. Bergmann, “Validity of estimates of myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography desite altered patterns of substrate utilization,” Journal of Nuclear Medicine, vol. 30, no. 2, pp. 187–193, 1989. View at Google Scholar · View at Scopus
  73. S. A. J. Timmer, M. Lubberink, T. Germans et al., “Potential of [11C]acetate for measuring myocardial blood flow: studies in normal subjects and patients with hypertrophic cardiomyopathy,” Journal of Nuclear Cardiology, vol. 17, no. 2, pp. 264–275, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. K. Leung, “[11C]Acetate,” 2004.
  75. W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk, “Myocardial substrate metabolism in the normal and failing heart,” Physiological Reviews, vol. 85, no. 3, pp. 1093–1129, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. S. R. Bergmann, “Imaging of myocardial fatty acid metabolism with PET,” Journal of Nuclear Cardiology, vol. 14, no. 3, pp. S118–S124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. D. R. Bielefeld, T. C. Vary, and J. R. Neely, “Inhibition of carnitine palmitoyl-CoA transferase activity and fatty acid oxidation by lactate and oxfenicine in cardiac muscle,” Journal of Molecular and Cellular Cardiology, vol. 17, no. 6, pp. 619–625, 1985. View at Google Scholar · View at Scopus
  78. G. L. Bartels, W. J. Remme, and H. R. Scholte, “Acute myocardial ischaemia induces cardiac carnitine release in man,” European Heart Journal, vol. 18, no. 1, pp. 84–90, 1997. View at Publisher · View at Google Scholar · View at Scopus
  79. G. Angsten, S. Valind, R. Takalo, H. Neu, S. Meurling, and B. Långström, “Inhibition of carnitine-acyl transferase I by oxfenicine studied in vivo with [11C]-labeled fatty acids,” Nuclear Medicine and Biology, vol. 32, no. 5, pp. 495–503, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. M. M. Ter-Pogossian, M. S. Klein, J. Markham, R. Roberts, and B. E. Sobel, “Regional assessment of myocardial metabolic integrity in vivo by position-emission tomography with 11C-labeled palmitate,” Circulation, vol. 61, no. 2, pp. 242–255, 1980. View at Publisher · View at Google Scholar · View at Scopus
  81. E. M. Geltman, “Metabolic imaging of patients with cardiomyopathy,” Circulation, vol. 84, no. 3, pp. I265–I272, 1991. View at Google Scholar · View at Scopus
  82. T. R. DeGrado, H. H. Coenen, and G. Stocklin, “14(R,S)-[18F]Fluoro-6-thia-heptadecanoic acid (FTHA): evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids,” Journal of Nuclear Medicine, vol. 32, no. 10, pp. 1888–1896, 1991. View at Google Scholar · View at Scopus
  83. M. Taylor, T. R. Wallhaus, T. R. Degrado et al., “An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure,” Journal of Nuclear Medicine, vol. 42, no. 1, pp. 55–62, 2001. View at Google Scholar · View at Scopus
  84. B. Renstrom, S. Rommelfanger, C. K. Stone et al., “Comparison of fatty acid tracers FTHA and BMIPP during myocardial ischemia and hypoxia,” Journal of Nuclear Medicine, vol. 39, no. 10, pp. 1684–1689, 1998. View at Google Scholar · View at Scopus
  85. T. R. DeGrado, M. T. Kitapci, S. Wang, J. Ying, and G. D. Lopaschuk, “Validation of 18F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: effects of hypoxia and composition of exogenous fatty acids,” Journal of Nuclear Medicine, vol. 47, no. 1, pp. 173–181, 2006. View at Google Scholar · View at Scopus
  86. T. R. DeGrado, F. Bhattacharyya, M. K. Pandey, A. P. Belanger, and S. Wang, “Synthesis and preliminary evaluation of 18-18F-fluoro-4-thia- oleate as a PET probe of fatty acid oxidation,” The Journal of Nuclear Medicine, vol. 51, no. 8, pp. 1310–1317, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. L. H. Opie, “Effects of regional ischemia on metabolism of glucose and fatty acids. Relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia,” Circulation Research, vol. 38, no. 5, pp. 52–74, 1976. View at Google Scholar · View at Scopus
  88. P. Camici, E. Ferrannini, and L. H. Opie, “Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography,” Progress in Cardiovascular Diseases, vol. 32, no. 3, pp. 217–238, 1989. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Iida, U. Ruotsalainen, M. Mäki et al., “F-18 fluorodeoxyglucose uptake and water-perfusable tissue fraction in assessment of myocardial viability,” Annals of Nuclear Medicine, vol. 26, no. 8, pp. 644–655, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Bousquenaud, F. Maskali, S. Poussier et al., “Acipimox-enhanced 18F-fluorodeoxyglucose positron emission tomography for characterizing and predicting early remodeling in the rat infarct model,” International Journal of Cardiovascular Imaging, vol. 28, no. 6, pp. 1407–1415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. M. J. Knuuti, H. Yki-Jarvinen, L.-. Voipio-Pulkki et al., “Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative,” Journal of Nuclear Medicine, vol. 35, no. 6, pp. 989–998, 1994. View at Google Scholar · View at Scopus
  92. M. J. Knuuti, P. Nuutila, U. Ruotsalainen et al., “The value of quantitative analysis of glucose utilization in detection of myocardial viability by PET,” Journal of Nuclear Medicine, vol. 34, no. 12, pp. 2068–2075, 1993. View at Google Scholar · View at Scopus
  93. A. Tawakol, R. Q. Migrino, G. G. Bashian et al., “In vivo18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients,” Journal of the American College of Cardiology, vol. 48, no. 9, pp. 1818–1824, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. E. J. Battegay, “Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects,” Journal of Molecular Medicine, vol. 73, no. 7, pp. 333–346, 1995. View at Google Scholar · View at Scopus
  95. P. Carmeliet and R. K. Jain, “Molecular mechanisms and clinical applications of angiogenesis,” Nature, vol. 473, no. 7347, pp. 298–307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. M. A. Schwartz, M. D. Schaller, and M. H. Ginsberg, “Integrins: emerging paradigms of signal transduction,” Annual Review of Cell and Developmental Biology, vol. 11, pp. 549–599, 1995. View at Publisher · View at Google Scholar · View at Scopus
  97. P. C. Brooks, R. A. F. Clark, and D. A. Cheresh, “Requirement of vascular integrin αvβ3 for angiogenesis,” Science, vol. 264, no. 5158, pp. 569–571, 1994. View at Publisher · View at Google Scholar · View at Scopus
  98. W. Cai and X. Chen, “Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression,” Frontiers in Bioscience, vol. 12, no. 11, pp. 4267–4279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. U. Tateishi, T. Oka, and T. Inoue, “Radiolabeled RGD peptides as integrin alpha(v)beta3-targeted PET tracers,” Current Medicinal Chemistry, vol. 19, no. 20, pp. 3301–3309, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. M. R. Stacy, M. W. Maxfield, and A. J. Sinusas, “Targeted molecular imaging of angiogenesis in PET and SPECT: a review,” Yale Journal of Biology and Medicine, vol. 85, no. 1, pp. 75–86, 2012. View at Google Scholar · View at Scopus
  101. M. Rodriguez-Porcel, W. Cai, O. Gheysens et al., “Imaging of VEGF receptor in a rat myocardial infarction model using PET,” Journal of Nuclear Medicine, vol. 49, no. 4, pp. 667–673, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. B. Wagner, M. Anton, S. G. Nekolla et al., “Noninvasive characterization of myocardial molecular interventions by integrated positron emission tomography and computed tomography,” Journal of the American College of Cardiology, vol. 48, no. 10, pp. 2107–2115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. H. Gao, L. Lang, N. Guo et al., “PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 4, pp. 683–692, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. M. R. Makowski, U. Ebersberger, S. Nekolla, and M. Schwaiger, “In vivo molecular imaging of angiogenesis, targeting α vβ3 integrin expression, in a patient after acute myocardial infarction,” European Heart Journal, vol. 29, no. 18, p. 2201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Haubner, W. A. Weber, A. J. Beer et al., “Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD,” PLoS Medicine, vol. 2, article e70, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Almutairi, R. Rossin, M. Shokeen et al., “Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 3, pp. 685–690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Hori, S. Sasayama, A. Kitabatake et al., “Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial,” American Heart Journal, vol. 147, no. 2, pp. 324–330, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. R. M. de Jong, A. T. M. Willemsen, R. H. J. A. Slart et al., “Myocardial β-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[11C]CGP12388,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 4, pp. 443–447, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Naya, T. Tsukamoto, K. Morita et al., “Myocardial β-adrenergic receptor density assessed by 11C-CGP12177 PET predicts improvement of cardiac function after carvedilol treatment in patients with idiopathic dilated cardiomyopathy,” Journal of Nuclear Medicine, vol. 50, no. 2, pp. 220–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. D. S. Goldstein, J. E. Brush Jr., G. Eisenhofer, R. Stull, and M. Esler, “In vivo measurement of neuronal uptake of norepinephrine in the human heart,” Circulation, vol. 78, no. 1, pp. 41–48, 1988. View at Publisher · View at Google Scholar · View at Scopus
  111. G. J. Hasking, M. D. Esler, G. L. Jennings, D. Burton, J. A. Johns, and P. I. Korner, “Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity,” Circulation, vol. 73, no. 4, pp. 615–621, 1986. View at Publisher · View at Google Scholar · View at Scopus
  112. S. Li, C. Holmes, I. J. Kopin, and D. S. Goldstein, “Aging-related changes in cardiac sympathetic function in humans, assessed by 6-18F-fluorodopamine PET scanning,” The Journal of Nuclear Medicine, vol. 44, no. 10, pp. 1599–1603, 2003. View at Google Scholar · View at Scopus
  113. D. S. Goldstein, C. Holmes, J. E. Stuhlmuller, J. W. M. Lenders, and I. J. Kopin, “6-[18F]Fluorodopamine positron emission tomographic scanning in the assessment of cardiac sympathoneural function—studies in normal humans,” Clinical Autonomic Research, vol. 7, no. 1, pp. 17–29, 1997. View at Publisher · View at Google Scholar · View at Scopus
  114. D. D. Gutterman, D. A. Morgan, and F. J. Miller, “Effect of brief myocardial ischemia on sympathetic coronary vasoconstriction,” Circulation Research, vol. 71, no. 4, pp. 960–969, 1992. View at Google Scholar · View at Scopus
  115. A. J. Luisi Jr., G. Suzuki, R. DeKemp et al., “Regional 11C-hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction,” Journal of Nuclear Medicine, vol. 46, no. 8, pp. 1368–1374, 2005. View at Google Scholar · View at Scopus
  116. D. M. Raffel, R. A. Koeppe, Y. W. Jung et al., “Quantification of cardiac sympathetic nerve density with N-11C-guanyl-meta-octopamine and tracer kinetic analysis,” Journal of Nuclear Medicine, vol. 54, pp. 1645–1652, 2013. View at Google Scholar
  117. H. R. Herschman, “Molecular Imaging: looking at Problems, Seeing Solutions,” Science, vol. 302, no. 5645, pp. 605–608, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. F. Nensa, T. D. Poeppe, K. Beiderwellen et al., “Hybrid PET/MR imaging of the heart : feasibility and initial results,” Radiology, vol. 268, no. 2, pp. 366–373, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. S. G. Nekolla, A. Martinez-Moeller, and A. Saraste, “PET and MRI in cardiac imaging: from validation studies to integrated applications,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 1, pp. 121–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. B. R. Jarrett, B. Gustafsson, D. L. Kukis, and A. Y. Louie, “Synthesis of 64Cu-labeled magnetic nanoparticles for multimodal imaging,” Bioconjugate Chemistry, vol. 19, no. 7, pp. 1496–1504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. H. Lee, Z. Li, K. Chen et al., “PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles,” The Journal of Nuclear Medicine, vol. 49, no. 8, pp. 1371–1379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. T. Schindler and H. Schelbert, “Quantitation of myocardial perfusion: absolute blood flow versus relative uptake,” in Atlas of Nuclear Cardiology, V. Dilsizian and J. Narula, Eds., pp. 145–194, Springer, New York, NY, USA, 2013. View at Google Scholar